Atlas Trials

Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Clinical trial NCT04624113 · TERMINATED

Trial details

NCT number
NCT04624113
Sponsor
Washington University School of Medicine
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Head and Neck Squamous Cell Carcinoma
Start date
2021-04-14
Primary completion
2022-08-09
Enrollment
13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.